Price Volatility is mainly due to the Fundamental Analysis. Not a lot to say on Technical Analysis
Vaxart Inc. VXRT, +28.43% said Friday its oral COVID-19 vaccine has been selected to take part in a nonhuman primate challenge study funded by the U.S. government’s ‘Operation Warp Speed’ program, that aims to accelerate development of a vaccine. Shares were up more than 28%.
VXRT
Vaxart Inc. VXRT, +28.43% said Friday its oral COVID-19 vaccine has been selected to take part in a nonhuman primate challenge study funded by the U.S. government’s ‘Operation Warp Speed’ program, that aims to accelerate development of a vaccine. Shares were up more than 28%.
VXRT